Summary
- Current Price
- As of today, NBIX price is $154.49, up +2.43% on
- Current Price All-Time High
- NBIX price is currently -16.99% below its historical high of $186.12 set on
- Market Cap
- NBIX current market cap is $16B, up +20.80% over the past 365 days
- PE Ratio
- NBIX current PE ratio is 22.63
- Revenue
- NBIX current annual revenue is $2.86B, up +21.45% year-over-year
- Next Earnings
- The next earnings release for NBIX is on
Profile
| Metric | Value |
|---|---|
| Full Name | Neurocrine Biosciences, Inc. |
| Ticker | NASDAQ: NBIX |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Specialty & Generic Drug Manufacturers |
| Country | United States |
| IPO | |
| Indexes | Not included |
| Website | neurocrine.com |
| Employees | 1,800 |
Key Metrics
| Metric | Value | Date |
|---|---|---|
| Price | $154.49 | |
| Price, 1D Change | +2.43% | |
| Market Cap | $16B | |
| - | ||
| PE Ratio | 22.63 | |
| Beta | 0.63 | |
| Revenue | $2.86B | |
| Revenue, 1Y Change | +21.45% | |
| EPS | $4.67 | |
| EPS, 1Y Change | +41.87% |
Chart
SUGGESTED SERIES
Events
| Metric | Value | Date |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | N/A | N/A |
| Next Split | N/A | N/A |
| Last Ticker Change | N/A | N/A |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Value | Date |
|---|---|---|
| EPS | $4.67 | |
| EPS Estimate | $10.19 | N/A |
| EPS Est. Change | +118.21% | N/A |
| Revenue | $2.86B | |
| Revenue Estimate | $3.90B | N/A |
| Revenue Est. Change | +36.39% | N/A |
| Current Price | $154.49 | |
| Price Target | $215.00 | - |
| Price Tgt. Change | +39.17% | - |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $6.58 | $3.29 | -49.95% | |
| $6.81 | $4.67 | -31.48% | |
| $10.19 | N/A | +118.21% | |
| $11.95 | N/A | +156.01% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $2.36B | $2.36B | -0.04% | |
| $2.84B | $2.86B | +0.58% | |
| $3.90B | N/A | +36.39% | |
| $4.55B | N/A | +59.10% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Value | Date |
|---|---|---|
| Price, 1Y | +17.65% | |
| Price, 3Y | +46.35% | |
| Market Cap, 1Y | +20.80% | |
| Market Cap, 3Y | +52.42% | |
| Revenue, 1Y | +21.45% | |
| Revenue, 3Y | +92.15% | |
| EPS, 1Y | +41.87% | |
| EPS, 3Y | +198.89% |
🔒 Log In To Unlock Full Data
Technicals
| Metric | Value | Date |
|---|---|---|
| Current Price | $154.49 | |
| SMA 200 | $146.89 | |
| SMA 50 | $167.69 | |
| EMA 200 | $149.80 | |
| EMA 50 | $164.19 | |
| MACD | -$4.38 | |
| Beta | 0.63 | |
| ATR | $5.61 | |
| 14-Day RSI | 37.75 | |
| 10-Day Volatility | 33.55% |
Dividends
| Metric | Value | Date |
|---|---|---|
| - | N/A | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| $0.00 | ||
| 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Value | Date |
|---|---|---|
| Revenue | $2.86B | |
| EPS | $4.67 | |
| Gross Profit | $2.81B | |
| Gross Margin | 98.18% | |
| Operating Income | $636.50M | |
| Operating Margin | 22.25% | |
| Net Income | $478.60M | |
| Net Margin | 16.73% | |
| EBITDA | $666.60M |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Value | Date |
|---|---|---|
| Debt To Equity | 0.14 | |
| 3.39 | ||
| 3.30 | ||
| - | ||
| 6 | ||
| 7.91 |
Valuations
| Metric | Value | Date |
|---|---|---|
| PE Ratio | 22.63 | |
| 4.65 | ||
| 4.25 | ||
| 18.41 | ||
| - | N/A |
Balance Sheet
| Metric | Value | Date |
|---|---|---|
| Book Value | $3.25B | |
| $1.48B | ||
| $4.75B | ||
| $2.52B | ||
| $1.50B | ||
| $743.40M | ||
| Total Debt | $471.30M | |
| $56.00M | ||
| $104.90M |
Expenses
| Metric | Value | Date |
|---|---|---|
| $2.38B | ||
| $2.17B | ||
| $52.10M | ||
| $0.00 | ||
| $30.10M | ||
| $0.00 | ||
| $226.80M |
Cash Flow
| Metric | Value | Date |
|---|---|---|
| $782.70M | ||
| -$264.40M | ||
| -$38.30M | ||
| Capex | $34.00M | |
| $748.70M |
Recent analyst updates
| Metric | Value | Date |
|---|---|---|
| Morgan Stanley | → | |
| Wedbush | → | |
| Truist Securities | → | |
| Canaccord Genuity | → | |
| TD Cowen | → | |
| Stifel | → | |
| RBC Capital | → | |
| Piper Sandler | → | |
| Needham | → | |
| Morgan Stanley | → |
Analyst sentiment
Institutional ownership
Screeners with NBIX
FAQ
- What is the ticker symbol for Neurocrine Biosciences, Inc.?
- The ticker symbol for Neurocrine Biosciences, Inc. is NASDAQ:NBIX
- Does Neurocrine Biosciences, Inc. pay dividends?
- No, Neurocrine Biosciences, Inc. does not pay dividends
- What sector is Neurocrine Biosciences, Inc. in?
- Neurocrine Biosciences, Inc. is in the Healthcare sector
- What industry is Neurocrine Biosciences, Inc. in?
- Neurocrine Biosciences, Inc. is in the Specialty & Generic Drug Manufacturers industry
- What country is Neurocrine Biosciences, Inc. based in?
- Neurocrine Biosciences, Inc. is headquartered in United States
- When did Neurocrine Biosciences, Inc. go public?
- Neurocrine Biosciences, Inc. initial public offering (IPO) was on May 23, 1996
- Is Neurocrine Biosciences, Inc. in the S&P 500?
- No, Neurocrine Biosciences, Inc. is not included in the S&P 500 index
- Is Neurocrine Biosciences, Inc. in the NASDAQ 100?
- No, Neurocrine Biosciences, Inc. is not included in the NASDAQ 100 index
- Is Neurocrine Biosciences, Inc. in the Dow Jones?
- No, Neurocrine Biosciences, Inc. is not included in the Dow Jones index
- When was Neurocrine Biosciences, Inc. last earnings report?
- Neurocrine Biosciences, Inc.'s most recent earnings report was on July 30, 2026
- When does Neurocrine Biosciences, Inc. report earnings?
- The next expected earnings date for Neurocrine Biosciences, Inc. is October 28, 2026
Data Sources & References
- NBIX Official Website www.neurocrine.com
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/914475/000091447526000007/0000914475-26-000007-index.htm
- NBIX Profile on Yahoo Finance finance.yahoo.com/quote/NBIX
- NBIX Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/nbix
